|

MK-3120 Clinical Trials

4 actively recruiting trials across 4 locations

No change since May 2026

Also known as: SKB410

Pipeline

Phase 1/2: 4

Top Sponsors

  • Merck Sharp & Dohme LLC4

Indications

  • Cancer4
  • Bladder Cancer2
  • Urinary Bladder Neoplasms1
  • Malignant Neoplasm1
  • Urothelial Carcinoma1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

The University of Alabama at Birmingham ( Site 1005)

Phase 1/2

Bakersfield, California1 trial

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Michael G Oefelein Clinical Trials ( Site 0005)

Phase 1/2

Orange, California1 trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)

Phase 1/2

San Francisco, California1 trial

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

UCSF Medical Center at Mission Bay ( Site 5044)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.